Form 4: United Therapeutics CEO Exercises Options and Sells Shares Under 10b5-1 Plan
SEC Form 4 Filing
Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock options and sold shares on August 19, 2024, under a pre-arranged 10b5-1 trading plan.
Summary
- Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock options and sold shares of the company's common stock on August 19, 2024.
- The transactions were carried out under a pre-arranged 10b5-1 trading plan established on August 4, 2023.
- Rothblatt exercised 3,600 stock options at a price of $129.49 per share.
- She then sold a total of 3,600 shares in multiple transactions at prices ranging from $329.02 to $350.38.
- Following these transactions, Rothblatt directly owns 178 shares of common stock.
- Rothblatt also indirectly owns shares through various family trusts, including 166 shares by spouse, 245,909 shares by trust, 28,170 shares by trust, 324,518 shares by trust, and 45,596 shares by trust.
- The 10b5-1 trading plan is set to continue until the earlier of the exhaustion of 723,869 stock options expiring on December 31, 2024, or August 31, 2024.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by an insider. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.
Future Outlook
The reporting person's 10b5-1 trading plan will continue until the earlier of August 31, 2024, or the exhaustion of a tranche of 723,869 stock options that expire December 31, 2024.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions. The use of a 10b5-1 trading plan is a common practice for corporate executives to sell shares while avoiding accusations of insider trading.
Comparison to Industry Standards
- Executive compensation practices, including stock options and trading plans, are common across publicly traded companies, particularly in the biotech and pharmaceutical industries.
- Comparing Rothblatt's compensation and trading activity to CEOs of similar-sized biotech firms (e.g., BioMarin, Vertex) would provide context on whether these transactions are typical.
- The use of 10b5-1 plans is a standard practice, and the details of the plan (duration, number of shares, etc.) can be compared to those of executives at comparable companies.
Stakeholder Impact
- The transactions may have a minor impact on shareholders, potentially causing a slight decrease in share price due to the sale of shares.
- The transactions do not directly impact employees, customers, suppliers, or creditors.
Key Dates
| Date | Description |
|---|---|
| 2014-12-31 | Expiration date of stock options |
| 2023-08-04 | Date of establishment of the 10b5-1 trading plan |
| 2024-08-19 | Date of stock option exercise and share sales |
| 2024-08-21 | Date of signing of the Form 4 filing |
| 2024-08-31 | Potential end date of the 10b5-1 trading plan |
| 2024-12-31 | Expiration date of a tranche of 723,869 stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.